Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
Abstract Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC. Methods Web of Science, PubMed and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11112-w |
| _version_ | 1797784574302879744 |
|---|---|
| author | Xiaoqiang Gao Rui Zhao Huaxing Ma Shi Zuo |
| author_facet | Xiaoqiang Gao Rui Zhao Huaxing Ma Shi Zuo |
| author_sort | Xiaoqiang Gao |
| collection | DOAJ |
| description | Abstract Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC. Methods Web of Science, PubMed and Embase were retrieved for qualified literatures on the treatment of advanced HCC with atezolizumab plus bevacizumab until September 1, 2022. The outcomes included pooled overall response (OR), complete response (CR), partial response (PR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AEs). Results Twenty-three studies, comprising 3168 patients, were enrolled. The pooled OR, CR, and PR rates of the long-term (more than six weeks) therapy response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 26%, 2%, and 23%, respectively. The pooled OR, CR, and PR rates of the short-term (six weeks) therapeutic response evaluated with RECIST were 13%, 0%, and 15%, respectively. The pooled mOS and mPFS were 14.7 months and 6.66 months, respectively. During the treatment, 83% and 30% of patients experienced any grade AEs and grade 3 and above AEs, respectively. Conclusions Atezolizumab in combination with bevacizumab showed good efficacy and tolerability in the treatment of advanced HCC. Compared with short-term, non-first-line, and low-dose therapy, atezolizumab plus bevacizumab in long-term, first-line, and standard-dose treatment for advanced HCC showed a better tumor response rate. |
| first_indexed | 2024-03-13T00:41:50Z |
| format | Article |
| id | doaj.art-a81e1145cb6840b692686877868381c8 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-13T00:41:50Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-a81e1145cb6840b692686877868381c82023-07-09T11:16:22ZengBMCBMC Cancer1471-24072023-07-0123111310.1186/s12885-023-11112-wEfficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysisXiaoqiang Gao0Rui Zhao1Huaxing Ma2Shi Zuo3Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical UniversityDepartment of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical UniversityDepartment of Emergency Surgery, Affiliated Hospital of Guizhou Medical UniversityDepartment of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical UniversityAbstract Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC. Methods Web of Science, PubMed and Embase were retrieved for qualified literatures on the treatment of advanced HCC with atezolizumab plus bevacizumab until September 1, 2022. The outcomes included pooled overall response (OR), complete response (CR), partial response (PR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AEs). Results Twenty-three studies, comprising 3168 patients, were enrolled. The pooled OR, CR, and PR rates of the long-term (more than six weeks) therapy response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 26%, 2%, and 23%, respectively. The pooled OR, CR, and PR rates of the short-term (six weeks) therapeutic response evaluated with RECIST were 13%, 0%, and 15%, respectively. The pooled mOS and mPFS were 14.7 months and 6.66 months, respectively. During the treatment, 83% and 30% of patients experienced any grade AEs and grade 3 and above AEs, respectively. Conclusions Atezolizumab in combination with bevacizumab showed good efficacy and tolerability in the treatment of advanced HCC. Compared with short-term, non-first-line, and low-dose therapy, atezolizumab plus bevacizumab in long-term, first-line, and standard-dose treatment for advanced HCC showed a better tumor response rate.https://doi.org/10.1186/s12885-023-11112-wHepatocellular carcinomaAtezolizumabBevacizumabMeta-analysisSingle-arm |
| spellingShingle | Xiaoqiang Gao Rui Zhao Huaxing Ma Shi Zuo Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis BMC Cancer Hepatocellular carcinoma Atezolizumab Bevacizumab Meta-analysis Single-arm |
| title | Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis |
| title_full | Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis |
| title_fullStr | Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis |
| title_full_unstemmed | Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis |
| title_short | Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis |
| title_sort | efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world a single arm meta analysis |
| topic | Hepatocellular carcinoma Atezolizumab Bevacizumab Meta-analysis Single-arm |
| url | https://doi.org/10.1186/s12885-023-11112-w |
| work_keys_str_mv | AT xiaoqianggao efficacyandsafetyofatezolizumabplusbevacizumabtreatmentforadvancedhepatocellularcarcinomaintherealworldasinglearmmetaanalysis AT ruizhao efficacyandsafetyofatezolizumabplusbevacizumabtreatmentforadvancedhepatocellularcarcinomaintherealworldasinglearmmetaanalysis AT huaxingma efficacyandsafetyofatezolizumabplusbevacizumabtreatmentforadvancedhepatocellularcarcinomaintherealworldasinglearmmetaanalysis AT shizuo efficacyandsafetyofatezolizumabplusbevacizumabtreatmentforadvancedhepatocellularcarcinomaintherealworldasinglearmmetaanalysis |